iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. announce collaborative agreement to offer a combined service offering
iThemba Pharmaceuticals’ service division and Pyxis Discovery announced that they have signed a collaborative agreement to jointly market both companies’ services.
Pyxis’s computational chemistry and lead discovery expertise will be coupled with iThemba’s service division to provide medicinal and synthetic chemistry support to projects identified through Pyxis’ international client network. iThemba Pharmaceuticals and Pyxis Discovery also announced that they are entering into a co-marketing agreement to offer virtual libraries which will be exclusively synthesized for clients. Pyxis’s smart approach of designing and selecting compounds facilitates a rapid and efficient lead discovery and library design process and this coupled to iThemba’s expertise in synthetic and medicinal chemistry will provide our customers with a unique service offering opportunity.
“The intellectual and technological support from Pyxis will enhance both of our service offerings” said Chris Edlin, CSO of iThemba. “Our customers will gain the advantage of our coupled expertise in design, synthesis and medicinal chemistry prowess”.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Tuberous_sclerosis

Plant stress transformed into rapid tests for dangerous chemicals - Inexpensive method detects synthetic cannabinoids, banned pesticides
Evotec and Takeda enter into multi-year gene therapy research alliance
GxP Consulting Announces New Expansion Strategy into US and UK Markets

Fantastic muscle proteins and where to find them - “This is going to be unexpected even for myosin researchers”

Cancer Treatment with Built-in Light - Deep photodynamic therapy: photosensitizer irradiates itself
Silence Therapeutics Forms Scientific Advisory Board
InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways
Bayer Animal Health and Paraco agree on access to lead molecules

Wiggly proteins guard the genome - Dynamic network in the pores of the nuclear envelope blocks dangerous invaders

Defective immune cells in the brain cause Alzheimer’s disease - Scientists are studying the role of immune cell activation in Alzheimer's disease
